Tuberculosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
- Transparency Market Research
- Healthcare IT
Tuberculosis (TB) is an infectious disease, which is caused by Mycobacterium tuberculosis. These bacteria generally infect human lungs. However, it can infect other body parts/organs as well. Three major types of tuberculosis are found: latent, active, and drug-resistant tuberculosis. Symptoms are not identifiable in case of latent tuberculosis, due to presence of an inactive form of bacteria. In active tuberculosis, symptoms are clearly visible and they can spread from one person to another. Coughing for more than two weeks, chest pain, coughing up blood, chills, fatigue, unintentional weight loss, fever, and loss of appetite are some of the common symptoms of active tuberculosis. HIV/AIDS, severe kidney disease, cancer, diabetes, and malnutrition are some of the key risk factors generally found to be associated with tuberculosis.
Tuberculosis can be diagnosed with the help of tests including blood tests, imaging tests (such as chest X-ray or CT scan), and sputum tests. Tuberculosis can be treated with the first-line or second-line therapy. As per a report by World Health Organization (WHO), tuberculosis is one of the leading causes of deaths occurring worldwide. In 2015, approximately 9 million new cases of TB and 1.5 million deaths caused by TB occurred worldwide. Currently, WHO and certain government agencies are working toward reduction of tuberculosis burden globally, with the help of programs such as Stop TB. In December 2015, Multi-Drug Resistant Tuberculosis Program was also launched to check the tuberculosis prevalence across the globe.
Growing prevalence of multi-drug resistant tuberculosis is driving the tuberculosis drugs market. Drug shortages is a major restraint for the tuberculosis drugs market, especially in low- to medium-income countries of the world. Tuberculosis associated with diseases such as HIV/AIDS and conditions such as obesity is extremely difficult to manage. The tuberculosis drugs market can be segmented based on drug class, disease type, end-user, and region. In terms of drug class, the market can be categorized into first-line therapy, second-line therapy, and combination therapy. Isoniazid, Pyrazinamide, Rifampin, and Ethambutol majorly constitute the first-line therapy for TB; while Streptomycin, Capreomycin, Ethionamide, Levofloxacin, and Gatifloxacin are generally considered as a part of the second-line therapy. Second-line therapy is expected to be a rapidly growing segment of the tuberculosis drugs market.
Based on disease type, the tuberculosis drugs market can be segmented into latent tuberculosis, active tuberculosis, and drug-resistant tuberculosis. The drug-resistant tuberculosis segment is expected to expand rapidly during the forecast period. In terms of distribution channel, the market can be divided into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held the leading share in the global tuberculosis drugs market in 2016. The segment is projected to expand at a significant CAGR during the forecast period. The others segment is expected to gain a significant market share during the forecast period, due to launch of national government programs.
In terms of geography, the global tuberculosis drugs market can be categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global tuberculosis drugs market in 2016. Key factors responsible for growth of the market in Asia Pacific are presence of large patient population and high incidence rate of TB, especially in some of the developing economies of the region such as India and China. On the other hand, North America and Europe have a relatively small-sized patient pool with lower incidence rate of the disease. However, high awareness, well-developed health care infrastructure, rapid adoption of advanced yet expensive TB tests, and high purchasing power are driving the market in these regions.
Key players operating in the global tuberculosis drugs market are Sanofi, Novartis AG, Bayer AG, Lupin Limited, Zydus Cadila, Merck & Co., Inc., Pfizer Inc., and AstraZeneca.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare IT
Healthcare ITGlobal mHealth Market Research Report 2016
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017